A candidate for a chikungunya vaccine is found to be generally safe and to elicit an immune response in the first phase 3 trial.

Published Date: 14 Jun 2023

A phase 3 randomized controlled trial reported in The Lancet found that the chikungunya vaccine candidate VLA1553 was generally well tolerated and elicited an immune response in 96% (263/266) of participants.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot